<DOC>
	<DOCNO>NCT00589927</DOCNO>
	<brief_summary>To evaluate whether cilostazol reduce neointimal hyperplasia ZES ( Zotarolimus-eluting stent ) implantation , investigator perform double-blind , randomize , multicenter , prospective study compare triple antiplatelet therapy ( aspirin plus clopidogrel plus cilostazol ) dual antiplatelet therapy ( aspirin plus clopidogrel ) 8 month patient long coronary lesion treat ZES .</brief_summary>
	<brief_title>Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent</brief_title>
	<detailed_description>Use drug-eluting stent ( DES ) reduce incidence restenosis rate need repeat revascularization compare use bare metal stent . DES implantation also significantly reduce angiographic restenosis patient long coronary lesions.However , although use DES decrease effect lesion length restenosis , restenosis DES implantation long coronary lesion remain high risk restenosis . Cilostazol , phosphodiesterase III inhibitor , know reduce smooth muscle proliferation intimal hyperplasia endothelial injury restenosis balloon angioplasty bare-metal stent ( BMS ) implantation compare aspirin clopidogrel ticlopidine . Recently , impact 6-month cilostazol treatment addition aspirin clopidogrel neointimal hyperplasia sirolimus- ( SES ) paclitaxel-eluting stent ( PES ) implantation long-coronary lesion evaluate institution . It report cilostazol treatment achieve primary end point ( in-stent late loss ) reduce need target lesion revascularization without significant adverse drug-side effect open-label design , suggest 6-month treatment cilostazol effectively inhibit neointimal hyperplasia DES implantation safely applied patient lesion high risk restenosis diabetes long lesions.However , study do unblinded manner might underestimate angiographic result due relatively short-term follow-up angiographic follow-up ( 6-month . Recently commercially available new-DES , zotarolimus-eluting stent ( ZES ) demonstrate significant reduction restenosis cardiac event 9-month . However , test 8-month treatment cilostazol also effectively inhibit neointimal hyperplasia ZES implantation patient long coronary lesion . Therefore , evaluate whether cilostazol reduce neointimal hyperplasia ZES implantation , investigator perform double-blind , randomize , multicenter , prospective study compare triple antiplatelet therapy ( aspirin plus clopidogrel plus cilostazol ) dual antiplatelet therapy ( aspirin plus clopidogrel ) 8 month patient long coronary lesion treat ZES .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Clinical 1 ) Patients angina documented ischemia patient document silent ischemia 2 ) Patients eligible intracoronary stenting 3 ) Age &gt; 18 year , &lt; 75 age 2 . Angiographic 1 ) De novo lesion 2 ) Percent diameter stenosis â‰¥50 % 3 ) Reference vessel size &gt; 2.5 mm visual estimation 4 ) Lesion length &gt; 25 mm visual estimation require long Endeavor stent implantation ( plan total stent length &gt; 30mm ) 1 . History bleed diathesis coagulopathy 2 . Pregnant 3 . Known hypersensitivity contraindication contrast agent , heparin , sirolimus paclitaxel 4 . Limited lifeexpectancy ( less 1 year ) due combine serious disease 5 . STelevation acute myocardial infarction 6 . Characteristics lesion 1 ) Left main disease 2 ) Instent restenosis 3 ) Graft vessel 7 . Hematological disease ( Neutropenia &lt; 3000/mm3 , Thrombocytopenia &lt; 100,000/mm3 ) 8 . Hepatic dysfunction , liver enzyme ( ALT AST ) elevation &gt; 3 time normal 9 . Renal dysfunction , creatinine &gt; 2.0mg/dL 10 . Contraindication aspirin , clopidogrel cilostazol 11. plan bifurcation stenting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stent</keyword>
	<keyword>cilostazol</keyword>
</DOC>